KAKenichiro Araki

Kenichiro Araki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kenichiro Araki has a total of 254 co-authors. Here are the top co-authors by number of shared publications:

  • Ken Shirabe

    60 shared publications
  • Mariko Tsukagoshi

    Division of Hepatobiliary and Pancreatic Surgery, Department of General Surgical Science, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, 371-8511, Gunma, Japan

    54 shared publications
  • Kei Hagiwara

    Division of Hepatobiliary and Pancreatic Surgery, Department of General Surgical Science, Graduate School of Medicine Gunma University Maebashi Japan

    52 shared publications
  • Takamichi Igarashi

    49 shared publications
  • Akira Watanabe

    Department of General Surgical Science, Division of Hepatobiliary and Pancreatic Surgery, Gunma University Graduate School of Medicine, Maebashi, Gunma 371‑8511, Japan

    48 shared publications
  • Norifumi Harimoto

    Division of Hepatobiliary and Pancreatic Surgery, Department of General Surgical Science, Gunma University Graduate School of Medicine, Gunma, Japan

    43 shared publications

Latest Publications

  • Open Access

    Impact of functional remnant liver volume on long-term outcomes after hepatectomy with bile duct resection for biliary tract cancer: Implications for a sequential portal and hepatic vein embolization strategy

    by Norihiro Ishii, Kenichiro Araki, Kohei Suto, Ryosuke Fukushima, Takayuki Okuyama, Ryo Muranushi, Kouki Hoshino, Mariko Tsukagoshi, Takamichi Igarashi, Norio Kubo, et al.

  • Surgical resection of a liver metastasis from an ovarian granulosa cell tumor mimicking a simple hepatic cyst

    by Takaomi Seki, Hideki Suzuki, Yoshiyasu Takayama, Satoshi Karino, Kenichiro Araki, Ken Shirabe

  • Open Access

    CD86 ‐Positive Mature Tertiary Lymphoid Structures Are Associated With CD8 + T‐Cell Infiltration and Favorable Clinical Outcomes in Pancreatic Ductal Adenocarcinoma

    by Takaomi Seki, Kenichiro Araki, Takehiko Yokobori, Hayato Ikota, Norio Kubo, Takamichi Igarashi, Mariko Tsukagoshi, Norihiro Ishii, Yasuo Hosouchi, Hiroshi Saeki, et al.

    Aims: Although tertiary lymphoid structures (TLSs) contribute to antitumor immunity, the significance of CD86 expression within mature TLSs in pancreatic ductal adenocarcinoma (PDAC) remains unclear. This study evaluated CD86‐positive mature TLSs as a marker of an immunologically active tumor microenvironment. Methods: We analyzed 128 treatment‐naive patients with PDAC who underwent curative resection. TLSs were evaluated by hematoxylin and eosin staining and immunohistochemistry for CD4, CD8, CD20, CD21, CD23, and CD86. TLS maturation, CD86 expression, TLS density and diameter, intratumoral T‐cell infiltration, and clinical outcomes were assessed. Multiplex immunofluorescence for CD8 and Granzyme B was performed in selected cases. Results: TLSs were identified in 124 patients. Among TLS‐positive cases, 13, 21, and 90 were classified as immature, intermediate, and mature TLSs, respectively. Mature TLSs were associated with increased intratumoral CD8 + T‐cell infiltration compared with TLS‐absent cases ( p = 0.027), whereas CD4 + T‐cell infiltration did not differ significantly. CD86‐positive mature TLSs were associated with higher intratumoral CD8 + T‐cell infiltration ( p = 0.002), greater TLS density, and larger TLS diameter than CD86‐negative mature TLSs. Multiplex immunofluorescence confirmed that most CD86‐positive cells co‐expressed CD20. Exploratory CD8/Granzyme B analysis suggested a higher proportion of Granzyme B‐expressing CD8 + T cells in CD86‐positive mature TLSs. Patients with CD86‐positive mature TLSs showed favorable clinical outcomes. Conclusion: CD86‐positive mature TLSs may represent a pathological feature associated with an immunologically active tumor microenvironment in PDAC, as reflected by increased intratumoral CD8 + T‐cell infiltration, a higher proportion of Granzyme B‐expressing CD8 + T cells in the exploratory analysis, and favorable clinical outcomes.

  • Open Access

    Achievement of the Ideal Outcome After Pancreatectomy for Pancreatic Ductal Adenocarcinoma Is Associated With Earlier Initiation and Higher Completion Rates of Adjuvant Chemotherapy and Improved Long‐Term Survival

    by Ryosuke Fukushima, Kenichiro Araki, Ryo Muranushi, Kouki Hoshino, Kei Hagiwara, Shunsuke Kawai, Mariko Tsukagoshi, Takamichi Igarashi, Norio Kubo, Ken Shirabe

    Background: The Ideal Outcome is a composite quality indicator reflecting optimal postoperative course after pancreatic surgery. This study aimed to clarify the prognostic significance of achieving the Ideal Outcome and its influence on the initiation and completion of adjuvant chemotherapy. Methods: We retrospectively analyzed 187 patients who underwent pancreatectomy for pancreatic ductal adenocarcinoma between 2016 and 2024. The Ideal Outcome was defined as absence of in‐hospital mortality, severe complications, grade B or C postoperative pancreatic fistula, reoperation, prolonged hospitalization (> 75th percentile), or 30‐day readmission. Associations with survival, timing and completion of adjuvant chemotherapy, and predictors of non‐achievement of Ideal Outcome were assessed. Results: The Ideal Outcome was achieved in 56.7% of patients. Those who achieved it initiated adjuvant chemotherapy earlier and had significantly higher completion rates (64.2% vs. 43.2%; p = 0.004). In multivariate analysis, non‐achievement of the Ideal Outcome (HR = 1.82, 95% CI: 1.21–2.73; p = 0.004), tumor size ≥ 30 mm, and no adjuvant chemotherapy were independent prognostic predictors of poor overall survival. Similarly, non‐achievement of the Ideal Outcome (HR = 1.46, 95% CI: 1.14–2.35, p = 0.007), CA19‐9 ≥ 150 U/mL, tumor size ≥ 30 mm, and no adjuvant chemotherapy administration were identified as independent prognostic predictors of poor recurrence‐free survival. Age ≥ 80 years, cardiovascular disease, and soft pancreatic texture were independent predictors of not achieving the Ideal Outcome. Conclusions: Achievement of the Ideal Outcome was associated with earlier initiation and higher completion rates of adjuvant chemotherapy, as well as improved long‐term survival after resection for pancreatic ductal adenocarcinoma.

  • Open Access

    Impact of Histopathological Response on Outcomes After Surgical Resection Following Carbon‐Ion Radiotherapy for Pancreatic Cancer With Arterial Involvement

    by Kenichiro Araki, Norio Kubo, Yuhei Miyasaka, Hayato Ikota, Ryo Muranushi, Mariko Tsukagoshi, Takamichi Igarashi, Masahiko Okamoto, Tatsuya Ohno, Ken Shirabe

    Aim: Carbon‐ion radiotherapy (CIRT) provides superior dose distribution and higher biological effectiveness than conventional X‐ray radiotherapy and has emerged as a promising component of multidisciplinary treatment for advanced pancreatic ductal adenocarcinoma (PDAC). However, evidence regarding surgical resection after CIRT remains limited. In this study, we aimed to evaluate the feasibility, histopathological therapeutic response, and oncological outcomes of pancreatic resection after CIRT‐based multimodal treatment. Methods: We retrospectively analyzed 12 patients with borderline resectable pancreatic cancer with arterial involvement (BR‐A) or unresectable locally advanced PDAC (UR‐LA), who underwent surgical resection following CIRT at our institution between January 2016 and June 2025. The surgical outcomes, perioperative morbidity, pathological therapeutic responses, and survival outcomes were assessed. Results: Surgical resection after CIRT was feasible in all patients. The procedures included pancreaticoduodenectomy ( n = 5), distal pancreatectomy ( n = 2), and distal pancreatectomy with celiac axis resection ( n = 5). R0 resection was achieved in 11 patients (92%) and no pathological lymph node metastasis was identified. A marked histopathological response (Evans Grades III–IV) was observed in 83% of patients. No local recurrences were observed in the CIRT irradiation field. The 3‐year progression‐free survival and overall survival (OS) rates calculated from treatment initiation were 74.1% and 79.5%, respectively, whereas the corresponding 3‐year recurrence‐free survival and OS rates calculated from surgical resection were 47.6% and 50.8%, respectively. Conclusions: Surgical resection following CIRT‐based multimodal treatment is feasible and safe, achieving a favorable histopathological response and durable local control in selected patients with PDAC with arterial involvement.

  • Open Access

    Prediction of Long‐Term Prognosis in Patients With Hepatocellular Carcinoma Using the National Clinical Database Risk Calculator

    by Mariko Tsukagoshi, Kenichiro Araki, Norio Kubo, Takamichi Igarashi, Shunsuke Kawai, Kei Hagiwara, Kouki Hoshino, Ryo Muranushi, Ken Shirabe

    Aim: To determine the value of the National Clinical Database (NCD) risk calculator for predicting surgical outcomes and long‐term prognosis in patients undergoing resection for hepatocellular carcinoma (HCC). Methods: We retrospectively analyzed data from 210 patients with HCC who underwent initial hepatic resection between January 2016 and December 2022. We calculated predicted incidence of surgery‐related mortality (predicted mortality rate) using the NCD risk calculator. We assessed the relationship between predicted mortality rate and clinicopathological factors, including their relationship with long‐term prognosis. Results: A predicted mortality rate of ≥ 3% significantly correlated with worse recurrence‐free survival and overall survival (OS), with a high‐risk group showing increased blood loss, longer hospital stays, and higher severe complication rates. Multivariate analysis identified predicted mortality rate of ≥ 3% as an independent prognostic indicator for poor OS, alongside male sex and microvascular invasion. Conclusion: The NCD risk calculator showed potential to predict not only short‐term outcomes but also long‐term prognosis in patients with HCC undergoing resection. The NCD risk calculator may be a valuable complementary tool for decision‐making about liver resection in patients with HCC.

  • Open Access

    Feasibility Study of Combined Systemic Therapy and Carbon‐Ion Radiotherapy for Hepatocellular Carcinoma Patients

    by Daijiro Kobayashi, Kei Shibuya, Yuhei Miyasaka, Kenichiro Araki, Yuichi Yamazaki, Ken Shirabe, Tatsuya Ohno

    Background: Recent advances in systemic therapy, including tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs), have improved outcomes for hepatocellular carcinoma (HCC) and enabled downstaging strategies that allow subsequent local treatments. Carbon‐ion radiotherapy (CIRT) can provide excellent tumor control with minimal impairment of liver function. However, the feasibility and safety of combining systemic therapy with CIRT have not been well evaluated. Methods: We retrospectively reviewed 21 patients with HCC who received CIRT integrated with systemic therapy at a single institution. Systemic therapy consisted of TKIs or ICIs and was administered either before or after CIRT, reflecting real‐world clinical practice. The primary endpoint was feasibility and safety, assessed by the incidence of adverse events (AEs) graded by CTCAE v5.0 and changes in albumin–bilirubin (ALBI) and Child–Pugh scores. Secondary endpoints included overall survival (OS), progression‐free survival (PFS), and local control (LC). Results: No grade ≥ 4 AEs were observed during peri‐radiotherapeutic integration of systemic therapy and CIRT. The most frequent AEs were grade 1 fatigue, radiation pneumonitis, and hepatobiliary disorders. Neither ALBI nor Child–Pugh scores showed clinically meaningful deterioration after CIRT, indicating preserved liver function. The 1‐year OS, PFS, and LC rates were 59.0%, 28.6%, and 70.6%, respectively. Despite large tumor burdens (median GTV 93.2 cm 3 ) and variable baseline liver function, treatment was generally well tolerated. Conclusions: Integration of CIRT with systemic therapy was feasible and demonstrated an acceptable safety profile without worsening liver function. This multimodal approach may represent a treatment option for selected patients with HCC, particularly in downstaging or locally advanced settings. Prospective studies are needed to validate these findings.

  • Poor-contrast areas in lymph nodes on contrast-enhanced computed tomography scan/magnetic resonance imaging are predictive of lymph node metastasis in patients with resected intrahepatic cholangiocarcinoma

    by Kei Hagiwara, Kenichiro Araki, Norio Kubo, Takamichi Igarashi, Mariko Tsukagoshi, Kei Shibuya, Hiroyasu Asanaga, Natsumi Katsumata, Masashi Ebara, Azusa Tokue, et al.

    Intrahepatic cholangiocarcinoma (ICC) with pathological lymph node metastasis (LNM) is associated with a poor prognosis. The standard treatment for ICC is surgical resection; however, the importance of prophylactic lymph node dissection (LND) is unclear. This study examined the predictive value of preoperative imaging for LNM from ICC. Forty patients with ICC underwent preoperative diagnostic imaging using contrast-enhanced computed tomography (CT), gadoxetic acid-enhanced magnetic resonance imaging (EOB-MRI), and positron emission tomography (PET)-CT, followed by liver resection with LND. Lymph node (LN) size (≥ 10 mm) and the presence of poor-contrast areas in LNs were evaluated using CT and EOB-MRI. Visually assessed positive LNs were evaluated by PET-CT. LN size measured on CT and EOB-MRI could not predict pathological LNM. However, poor-contrast areas in LNs measured on CT (sensitivity, 55.0%; specificity, 95.0%) and EOB-MRI (sensitivity, 75.0%; specificity, 95.0%) could predict pathological LNM (pLNM), as could visually assessed positive LNs measured on PET-CT (sensitivity, 50.0%; specificity, 100.0%). LNs with poor-contrast areas measured on CT or MRI were an independent predictor of pLNM. LNM was predicted by evaluating LNs with poor-contrast areas using contrast-enhanced CT or EOB-MRI. Thus, LNM risk should be assessed using EOB-MRI or/and contrast-enhanced CT scans before surgery.

  • Expert Survey on Chyle Leakage After Pancreaticoduodenectomy: The Precision Anatomy for Minimally Invasive Hepato‐Biliary‐Pancreatic Surgery ( PAM ‐ HBP Surgery) Project 2024

    by Hitoe Nishino, Atsushi Oba, Keiichi Akahoshi, Taiga Wakabayashi, Chang Moo Kang, Shin‐E. Wang, Deeksha Kapoor, Benedict Kinny‐Köster, Ramiro Fernández‐Placencia, Yasuko Matsuo, et al.

    Background/Purpose: Chyle leakage (CL) after pancreaticoduodenectomy (PD) remains an underestimated complication with a consistent incidence. This expert survey analyzed its occurrence from anatomical and surgical perspectives. Methods: A structured survey was distributed to 57 surgeons from 10 countries, with extensive experience in open and minimally‐invasive pancreatectomy. Results: Most experts reported CL incidence as: open ≥ laparoscopic, open > robotic, and laparoscopic = robotic. They identified three major anatomical pitfalls: (i) the transverse mesocolon on the ventral side of the superior mesenteric artery and vein (SMA/SMV), (ii) the meso‐jejunum on the dorsal side of the SMA/SMV, and (iii) the fusion fascia of Treitz on the ventral side of the inferior vena cava (IVC). For lymphatic dissection and control, energy devices were favored across all approaches, whereas ligation was more common in open PD and clipping more frequent in robotic PD. Opinions on the optimal dissection plane at the fusion fascia of Treitz varied: along the pancreatic surface (21%), within the fascia (31%), or exposing the IVC (38%). Conclusions: Expert opinions suggest that the incidence of CL after PD does not differ significantly between open and minimally invasive approaches. Consensus emerged regarding common anatomical pitfalls, which may inform strategies for prevention.

  • Global Survey of Technical Preferences for Robotic Versus Laparoscopic Segmentectomy of Liver Segments 7 and 8: A 2024 PAM ‐ HBP Surgery Project

    by Keiichi Akahoshi, Taiga Wakabayashi, Hitoe Nishino, Atsushi Oba, Paolo Magistri, Kenichiro Araki, Kwangpyo Hong, Ruben Ciria, Iswanto Sucandy, Catherine Teh, et al.

    Background: Segmentectomy of liver segments 7 and 8 (S7/8) is technically challenging due to their posterosuperior location and proximity to major hepatic veins. With the increasing adoption of robotic surgery, current practices for S7/8 resection across different surgical modalities remain unclear. Methods: An international web‐based survey was conducted in 2024 among expert hepatobiliary surgeons. The 18‐item questionnaire addressed institutional policies, technical preferences, and procedural strategies for laparoscopic and robotic S7/8 segmentectomy. Results: A total of 67 surgeons from 11 countries responded. Among them, 51% had performed over 20 laparoscopic S7/8 resections, whereas 57% had no experience with the robotic approach. Robotic S7/8 segmentectomy accounted for fewer than 20% of cases at most institutions. The Glissonean approach from the hilum and the Maryland bipolar dissector were more frequently used in robotic procedures. The cranio‐dorsal approach to the right hepatic vein was less common in robotic surgery, while the cranio‐ventral approach to the middle hepatic vein was common to both modalities. Conclusions: Robotic S7/8 segmentectomy remains in the early stages of adoption despite ergonomic and technical advantages. This international survey highlights distinct technical differences between laparoscopic and robotic approaches, emphasizing the need for targeted training and standardized device integration.